5th Sep 2018 08:28
LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.
The National Medical Products Administration of China granted the biopharmaceutical company drug registration for the capsules, which will be marketed as Elunate.
Elunate will be used as a oral treatment option for colorectal cancer in patients who have failed at least two prior therapies, the company said.
Chairman Simon To said: "Today's approval is a major achievement for Chi-Med. Elunate is the first home-grown, China-discovered and developed drug we are aware of in an oncology indication to be unconditionally approved through a randomized clinical trial in China."
The approval came as a result of a clinical trial of the drug which showed "a statistically significant and clinically meaningful improvement in overall survival versus placebo", the company said.
Hutchison shares were trading up 3.3% at 4,660.00 pence each early Monday morning.
Related Shares:
Hutchmed